(TheNewswire)
Thetford Mines, Quebec / TheNewswire / June 1
st , 2018 - KDA Group Inc. (TSXV: KDA) (“ KDA Group ” or the “ Corporation ”) is
proud to announce an agreement with ZoomMed Inc. (TSXV: ZMD) (“ ZoomMed
”) whereby KDA Group can distribute under a non-exclusive license the ZRx Prescriber developed by ZoomMed in the
United States. The Corporation and ZoomMed are also expecting to conclude, shortly, a joint venture agreement in order to unite
their expertise for the development and commercialization of the ZRx Prescriber in the US market. KDA Group and ZoomMed are arms’
length parties.
KDA Group will issue ZoomMed 10,000,000 common class A shares of its share capital (the “
Common Shares ”) at a deemed value of $1,720,000 CND, based on the average closing price
of the Common Shares for the last 52 weeks to April 30 th , 2018, being $ 0.172 CND
per Common Share. In addition, ZoomMed will be entitled to receive royalties, up to US $2,500,000 under certain terms and
conditions. The Common Shares will be subject to a four month and one day mandatory holding period.
"This agreement will accelerate the growth of ZoomMed’s healthcare solutions in the vast US market
estimated at more than 800 million US dollars. The expertise of KDA Group’s management and the team of its subsidiary
pharmaceutical communication will definitely be an additional strategic key to our success," said Mr. Yves Marmet, President and
CEO of ZoomMed.
"Our subsidiary’s mission is to provide excellence at all times through the distribution of
educational and communication programs in the medical field, from the development to the implementation of strategies offered to
large pharmaceutical companies for the purpose of improving patients’ health. Thanks to ZoomMed's technology platform, we will be
able to expand our service offerings to physicians and patients in the US market," said Marc Lemieux, President and CEO of KDA
Group.
"The e-prescribing market for 900,000 American physicians offers the perfect window of opportunity
for the commercialization of ZoomMed's software solution and business model”, added Mr . Lemieux.
The agreement and Common Shares issuance are subject to all required approvals including the final
approval of the TSX Venture Exchange.
About KDA Group
KDA Group is a leading solution and service provider to the pharmaceutical market for the distribution of
generic drugs and specialized solutions. Today, it is a respected name for quality and expertise among pharmacists. Its management
team is guided by a vision of continuing to lead the way in Quebec while extending operations across Canada and internationally.
Additional information on the Corporation is available at www.kdagroup.ca and on SEDAR at www.sedar.com .
About ZoomMed
ZoomMed builds and operates ZoomMed’s Communication Network, a clinical interoperable information exchange
network between physicians and the various other stakeholders of the healthcare sector, such as pharmacists, specialists,
pharmaceutical corporations and private insurers.
The cornerstone of this network is the ZRx Prescriber, an innovative Web technology application that greatly
simplifies prescription writing for physicians. Since it is a stand-alone product, it can easily be integrated into any Electronic
Medical Record (EMR) application.
- 30 –
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release from KDA Group contains forward-looking statements. Forward-looking statements
are typically identified by the words assumption , goal , guidance , objective , outlook , strategy , target, and other similar expressions, or
future or conditional verbs such as aim , anticipate , believe , predict , could , expect , intend , may
, plan , seek , should , strive, and will . By their nature, forward-looking statements require us to
make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other
factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these
estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore
subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in
the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press
release.
INFORMATION
Marc Lemieux
Chief Executive Officer
514 622-7370
info@groupekda.ca
Copyright (c) 2018 TheNewswire - All rights reserved.